BOSTON - Aug 22, 2025 (UTC) - Method AI, a medical technology company focused on improving oncology outcomes through image-guided surgical navigation, announced it has raised $20 million in Series A funding. The financing round, led by a private family office with participation from Cleveland Clinic and JobsOhio Growth Capital Fund, will support the continued development of Method AI’s novel surgical ultrasound platform designed to enhance visualization for robotic surgeons.
Funding Details
Method AI’s $20 million Series A funding round, announced on August 21, 2025, represents a significant step in advancing its AI-powered surgical navigation platform for oncology procedures. The round was led by a private family office, with participation from Cleveland Clinic and JobsOhio Growth Capital Fund, reflecting strong institutional support for Method AI’s mission to address critical visualization challenges in surgery.
“In complex oncology procedures, surgeons often have to remove tumors that are partially or completely embedded within the organ, making it extremely difficult to gauge the margins of the tumor during a live surgery,” said Doug Teany, Co-Founder and CEO of Method AI. “This incomplete view of the tumor and other critical anatomy leads to cancer left behind, unforeseen complications and loss of organ function. With the support of our investment partners, our technology can make the difference between completely removing a tumor or leaving part of it behind, which significantly impacts long-term patient outcomes.”
“Method AI’s platform addresses a critical gap in surgical navigation by providing real-time, AI-driven insights that go beyond what current systems can offer,” said Dr. Thomas Graham, Chief Innovation Officer at Cleveland Clinic and a member of Method AI’s board. “This investment will help scale a solution that has the potential to redefine how complex surgeries are performed.”
Strategic Goals and Use of Funds
Method AI will deploy the $20 million to achieve key strategic objectives, focusing on platform development, clinical validation, and market expansion. The planned initiatives include:
- Platform Enhancement: Advance the surgical ultrasound platform with improved AI algorithms for real-time 3D imaging and surgical planning.
- Clinical Validation: Expand clinical trials and partnerships with leading medical institutions to validate and refine the technology.
- Market Expansion: Scale commercial operations to reach more hospitals and surgical centers in the U.S. and explore international opportunities.
- Regulatory Approvals: Accelerate efforts to secure FDA and other regulatory clearances to ensure broad market access.
- Team Growth: Recruit top talent in AI, medical imaging, and clinical operations to support development and commercialization.
These efforts aim to position Method AI as a leader in AI-driven surgical navigation, enhancing precision and outcomes in oncology procedures.
Historical Funding and Growth
Method AI’s funding history reflects its rapid progress in the medical technology sector. The table below summarizes its known funding rounds:
| Round | Date | Amount | Lead Investor | Key Notes |
|---|---|---|---|---|
| Seed | June 2022 | $3M | Undisclosed | Supported initial platform development and early clinical pilots. |
| Series A | August 2025 | $20M | Private Family Office | Focused on platform enhancement, clinical validation, and market expansion. |
Founded in 2021 as a spinout from Cleveland Clinic, Method AI has made significant strides in developing its surgical ultrasound platform. The company has established partnerships with leading medical institutions and is gaining traction for its ability to address visualization challenges in robotic surgery, positioning it for growth in the oncology sector.
Method AI’s Technology
Method AI’s novel surgical ultrasound platform leverages artificial intelligence to enhance visualization during oncology procedures. Key features include:
- Real-Time 3D Imaging: Generates detailed 3D subsurface maps of organ anatomy, revealing structures beyond the view of traditional surgical cameras.
- AI-Generated Surgical Plans: Provides real-time guidance to surgeons, enhancing precision and decision-making during complex procedures.
- Continuous Ultrasound Imaging: Enables ongoing visualization throughout surgery, improving accuracy in robotic-assisted operations.
- Integration with Robotic Systems: Seamlessly connects with existing robotic surgical platforms to enhance compatibility and usability.
- Data-Driven Insights: Uses AI to analyze imaging data, supporting surgeons with predictive analytics and actionable recommendations.
The platform’s ability to visualize deep anatomy and provide real-time guidance sets it apart, addressing a critical gap in current surgical technologies.
Industry Impact and Challenges
Method AI’s platform is poised to transform oncology surgery by addressing longstanding visualization challenges, enabling surgeons to operate with greater precision and confidence. Early clinical feedback highlights its potential to improve patient outcomes by reducing complications and enhancing surgical accuracy, with the potential to reduce over $1 billion in annual healthcare costs. The platform’s adoption by leading institutions like Cleveland Clinic underscores its impact.
The medical technology sector is highly competitive, with companies like Intuitive Surgical and Medtronic leading in surgical robotics. Method AI must navigate challenges such as rigorous regulatory requirements, integration with existing systems, and the need for extensive clinical validation to gain widespread adoption.
Market Context and Industry Trends
The surgical robotics and navigation market is projected to reach $18.7 billion by 2027, driven by demand for precision, minimally invasive procedures, and AI integration. Key trends include:
- AI in Surgery: Growing adoption of AI for real-time imaging, predictive analytics, and surgical guidance.
- Minimally Invasive Techniques: Increasing preference for robotic-assisted surgeries that reduce recovery times and complications.
- Interoperability: Demand for platforms that integrate with existing surgical systems and hospital workflows.
- Personalized Surgery: Rising focus on tailored surgical plans based on patient-specific data.
- Regulatory Advancements: Evolving frameworks to support AI-driven medical technologies while ensuring safety.
Method AI’s platform aligns with these trends, positioning it to meet the needs of modern surgical environments.
Stakeholder Perspectives
Method AI’s leadership is focused on leveraging AI to redefine surgical precision, emphasizing collaboration with medical institutions to validate and scale the platform. Investors see significant potential in the company’s ability to address unmet needs in oncology surgery, driving both clinical and commercial success.
Stakeholder Insights
Stakeholders highlight Method AI’s innovative approach to surgical navigation, noting its potential to set a new standard in oncology procedures. The platform’s focus on real-time visualization and AI-driven guidance is seen as a game-changer for improving surgical outcomes and operational efficiency.
About Method AI
Founded in 2021 and headquartered in Boston, Massachusetts, Method AI is a medical technology company focused on improving oncology outcomes through AI-powered image-guided surgical navigation. Originating from Cleveland Clinic, the company develops a novel surgical ultrasound platform that provides real-time 3D imaging and guidance for robotic surgeons. Method AI’s mission is to empower surgeons with advanced visualization tools to enhance precision and patient outcomes.
Future Outlook
With the $20 million Series A funding, Method AI is well-positioned to accelerate its growth in 2025 and beyond. The company plans to expand clinical trials, secure regulatory approvals, and scale its platform to reach more surgical centers globally. By continuing to innovate and partner with leading institutions, Method AI aims to become a standard in AI-driven surgical navigation within the next five years.
For more information, visit https://www.methodsurgical.ai
Source : Method AI
